JasgitC(Chugh)SachdevMD

Oncology • Scottsdale, AZ

Director, Breast and GYN Early Trials

Join to view full profile

Dr. Sachdev is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sachdev's full profile

Already have an account?

Office
10510 N 92nd ST
Suite 200
Scottsdale, AZ 85258
Phone+1 480-323-1350

Fax+1 480-323-1359

Education & Training

University of TennesseeFellowship, Hematology and Medical Oncology, 2004 - 2007
Creighton University School of Medicine/Maricopa Medical Center (Phoenix)Residency, Internal Medicine, 2001 - 2004
Dayanand Medical College Class of 2000

Certifications & Licensure

AZ State Medical License 2010 - 2025
MS State Medical License 2007 - 2012
TN State Medical License 2007 - 2012
AR State Medical License 2008 - 2010

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013

Clinical Trials

Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery. Start of enrollment: 2008 Oct 01
Unknown status
Phase 2
Temsirolimus as Second-line Therapy in HCC Start of enrollment: 2010 Feb 01
Unknown status
Phase 2
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Start of enrollment: 2013 Apr 01
Terminated
Phase 1
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Start of enrollment: 2013 Apr 01
Terminated
Phase 1, Phase 2
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Start of enrollment: 2014 Aug 25
Completed
Phase 2
A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors Start of enrollment: 2014 Oct 11
Terminated
Phase 1
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 Start of enrollment: 2017 Oct 12
Active, not recruiting
Phase 1
Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers Start of enrollment: 2021 Dec 31
Withdrawn
Phase 1
Join now to see all

Publications & Presentations

PubMed

238 citations
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Hope S. Rugo, Jean Pierre Delord, Seock-Ah Im, Patrick A. Ott, Sarina Anne Piha-Paul
Clinical Cancer Research. 2018-06-15
8 citations
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Rebecca Arend, Jhalak Dholakia, Cesar Castro, Ursula Matulonis, Erika Hamilton
Gynecologic Oncology. 2023-05-01
291 citations
Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers
Johann S. de Bono, Ramesh K. Ramanathan, Lida Mina, Rashmi Chugh, John A. Glaspy
Cancer Discovery. 2017-02-27

Lectures

Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors.
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

Five Prime Therapeutics Presents Monotherapy Data from the Phase 1a/1b Trial of FPA150 in Patients with Advanced Solid Tumors at the 2019 ASCO Annual MeetingJune 1st, 2019
Dr. Jasgit Sachdev on What's on the Horizon for Ovarian CancerNovember 23rd, 2016
Lead Researcher Discusses Promising Antibody-Drug Conjugate for Ovarian CancerOctober 25th, 2016
Join now to see all